Abstract: An object of the present invention is to provide an anticancer drug capable of treating cancer by finding a target molecule specifically expressed in cancer cells and by specifically acting on the target molecule, and to provide a cancer testing method including a step of measuring the target molecule in a sample. The present invention provides an anticancer drug containing, as an active ingredient thereof, an anti-transmembrane protein 180 (TMEM-180) antibody or an antigen-binding fragment thereof. In addition, the present invention provides a cancer testing method including a step of measuring the amount of TMEM-180 in a sample collected from a subject.

Abstract: Applicant discloses an anti-idiotypic antibody to MOR202, which when fused to human albumin, shifted the anti-body in IFE thus mitigating any potential interference of MOR202 with the M-protein clinical assessment.

Abstract: The present invention generally relates to antibodies that bind to CD3, including multi specific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: An object of the present invention is to provide an anticancer drug capable of treating cancer by finding a target molecule specifically expressed in cancer cells and by specifically acting on the target molecule, and to provide a cancer testing method including a step of measuring the target molecule in a sample. The present invention provides an anticancer drug containing, as an active ingredient thereof, an anti-transmembrane protein 180 (TMEM-180) antibody or an antigen-binding fragment thereof. In addition, the present invention provides a cancer testing method including a step of measuring the amount of TMEM-180 in a sample collected from a subject.

Abstract: It was discovered that antigen-binding molecules comprising (i) a domain that binds to a molecule expressed on the surface of cells having immune response-suppressing functions, and (ii) a T cell receptor complex-binding domain exhibit more superior antitumor effects than conventional antigen-binding molecules by crosslinking T cells with cells having immune response-suppressing functions, and damaging the cells having immune response-suppressing functions.

Abstract: The presently disclosed subject matter provides antigen-binding proteins (e.g., chimeric antigen receptors) and antibodies or antigen-binding portions thereof that bind to a Foxp3 peptide/MHC molecule complex. Such antibodies, fusion proteins and conjugates thereof are useful for inhibiting regulatory T cells and treating cancers.

Abstract: Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.

Abstract: The present invention relates to a method for screening an anticancer agent which inhibits the binding of AIMP2-DX2 and HSP70. In addition, the pharmaceutical composition for preventing or treating cancer comprising, as an active ingredient, an anticancer agent screened according to the method of the present invention inhibits the expression of HSP70 or inhibits the binding of HSP70 and AIMP2-DX2, thereby lowering the level of AIMP2-DX2 protein, and can effectively prevent the progression of cancer. As such, the pharmaceutical composition can be useful for developing a cancer treating agent.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The instant invention provides for a new method of treating colorectal cancer (CRC) and metastases thereof in subjects, and preferably also of other solid cancers and metastases thereof in subjects, wherein said method preferably depends on whether the patient shows certain specific proteins levels in one or more body fluids prior to or during treatment, wherein said treatment comprises the administration of at least one pan ?v integrin inhibitor to a patient, a medicament for use in said new methods, and a method of predicting the outcome of a treatment with at least one pan ?v integrin inhibitor based on said specific protein levels in one or more body fluids of the patient.

Abstract: The present disclosure relates to a methods and systems for autonomous parking of vehicles (103). The vehicle receives an input signal for parking the vehicle in parking premises (100) comprising a plurality of parking space (102) having an elevated parking boundary indicator (101). The vehicle (103) obtains a map of the parking premises (100). Further, the vehicle (103) receives a plurality of LIDAR data points (205) of the parking premises (100) and identifies a plurality of linear patterns from the plurality of LIDAR data points (205). Thereafter, the vehicle (103) detects at least two linear patterns (401) from the plurality of linear patterns, having a predefined length and parallelly spaced apart, indicating the elevated parking boundary indicator (101) of an available parking space, where the vehicle (103) can be autonomously parked in the available parking space.

Abstract: Embodiments of the present disclosure are directed to systems and methods for determining a vehicle orientation. In one implementation, a computer-implemented method for determining a vehicle orientation may include receiving a first set of satellite signals associated with a connected device positioned relatively stationary with respect to a vehicle. The method may also include determining that the first set of satellite signals is insufficient to determine the vehicle orientation. The method may further include determining the vehicle orientation based on a first relative orientation of the connected device relative to the vehicle and a second relative orientation of the connected device relative to a reference object.

Abstract: One general aspect includes a system to establish a deployment force for an airbag of a vehicle, the system includes: a memory configured to include one or more executable instructions and a processor configured to execute the executable instructions, where the executable instructions enable the processor to carry out the following steps: monitoring a head position of a vehicle occupant; based on the monitored head position, calculating a distance of a body part of a vehicle operator relative to a portion of an interior cabin of the vehicle; and based on the distance of the body part, establishing the deployment force for the airbag.

Abstract: The presently disclosed subject matter provides antigen-binding proteins that specifically bind to Preferentially expressed antigen of melanoma (PRAME), including humanized, chimeric and fully human antibodies against PRAME, antibody fragments (e.g., scFv, Fab and F(ab)2), chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen-binding proteins and antibodies bind to a PRAME peptide/HLA class I molecule complex. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of PRAME associated diseases, including for example, breast cancer, ovarian cancer, melanoma, lung cancer, gastrointestinal cancer, brain tumor, head and neck cancer, renal cancer, myeloma, neuroblastoma, mantle cell lymphoma, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML), Non-Hodgkin lymphoma (NHL), and Chronic lymphocytic leukemia (CLL).

Abstract: A vehicle control system includes: a turning device that turns a wheel of a vehicle; a steering sensor that detects a driver's steering operation; and a control device configured to execute automated turning control that controls the turning device to automatically turn the wheel, independently of the driver's steering operation. A modification desire degree represents a degree to which the driver's steering operation modifies vehicle travel caused by the automated turning control. During execution of the automated turning control, the control device calculates the modification desire degree based on a result of detection by the steering sensor. When the modification desire degree exceeds a threshold, the control device executes system suppression processing without terminating the automated turning control. In the system suppression processing, the control device weakens the automated turning control as compared to a case where the modification desire degree is equal to or lower than the threshold.

Abstract: An inter-vehicle communication and driving assistance device performs wireless communication with other vehicles, and includes an inter-vehicle communication unit including a reception level detection unit, a position information reception unit, and an arithmetic processing unit. The arithmetic processing unit calculates inter-vehicle distances to other vehicles using latitude and longitude information of the other vehicles and the own vehicle, receives a position error radius, and acquires a reception level from the other vehicles. When a difference between the inter-vehicle distances is smaller than position error radius, a vehicle with a larger reception level is determined as a vehicle closer to the own vehicle. When the difference between the inter-vehicle distances is larger than the position error radius, a vehicle with a smaller inter-vehicle distance is determined as a vehicle closer to the own vehicle, and a distance to a leading vehicle is calculated.

Abstract: Upon detecting that an occupant has donned electronic smart glasses, an occupant protection system in a vehicle takes into account that the occupant is wearing electronic smart glasses.

Abstract: A vehicle includes at least one speaker, a camera configured to obtain a passenger's image, and a controller. The controller is configured to identify the passenger, to search for the identified passenger and emotion tag information related to a sound source output through the at least one speaker, and to control the at least one speaker or obtain passenger's emotional information according to the search result.

Abstract: One or more techniques and/or systems are disclosed for automatically obtaining a profile for a set of accelerator pedal position sensors in a target vehicle. The profile can comprise a correlation of the position of the pedal to an output signal for one or more sensor in the set of sensors. A pedal position sensor signal reader can be used to automatically detect signals from one or more pedal position sensor in the target vehicle's accelerator pedal, while the pedal is released, depressed, and moving between the released and depressed positions. A pedal profile can be automatically generated using the output signals and corresponding pedal positions. Obtained data can be used to program a speed control device for the target vehicle. Correlated output can be used to adjust the speed of the vehicle by sending an emulated signal to the ECM, which may adjust the speed control system.